When IMGN was making a run toward $18, IMGN managment announced a dilution sending IMGN price down to $12. When IMGN price was heading toward $16, right after the UBS conference, UBS analyst slams IMGN with a sell rating bringing IMGN into $13. Now, IMGN announces Royalty terms with Roche(they knew this for years) right before anticipated FDA approval dropping IMGN price by 20% to new lows. To small investors, these surprises are wiping us out financially. For the big boys (institutional investors), these news are no surprise and provides opportunity to accumulate on dips so when approval comes, they are laughing on their way to the bank counting your money. IMGN CEO is only loyal to his institutional friends, not you. We are so close to an approval, don't let the CEO and his cronies steal your shares. Unfortunately, IMGN ceo manipulation tactics are legal.
So why don't yas take yer profits when yas gots em???? Ya dingleberries oughta know by now what is gonna happen with this POS every time. IMGN is well known for the screwage factor and it comes as no surprise that it provided a screwage this time either. So stop yer beeiatchin and do something about it next time or just bend over now and hold the postition for the next buggaring. It is so tiring trying to teach SQUEEEEEEEEEALERS cause piggies NEVER learn.